Xencor (NASDAQ:XNCR) Now Covered by Analysts at William Blair

William Blair initiated coverage on shares of Xencor (NASDAQ:XNCR - Free Report) in a report issued on Monday, MarketBeat Ratings reports. The firm issued an outperform rating on the biopharmaceutical company's stock. William Blair also issued estimates for Xencor's Q1 2025 earnings at ($0.84) EPS, Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.01) EPS and FY2028 earnings at ($3.05) EPS.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company reduced their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $33.86.

Xencor Stock Performance

Shares of NASDAQ XNCR traded down $0.33 during mid-day trading on Monday, hitting $10.51. The stock had a trading volume of 463,505 shares, compared to its average volume of 627,704. The firm has a market cap of $740.56 million, a PE ratio of -3.28 and a beta of 0.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a 50 day moving average of $11.77 and a two-hundred day moving average of $18.43. Xencor has a twelve month low of $7.16 and a twelve month high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Research analysts predict that Xencor will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC grew its position in shares of Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after acquiring an additional 78,066 shares during the period. Geode Capital Management LLC grew its holdings in Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after purchasing an additional 17,658 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of Xencor in the third quarter valued at approximately $540,000. JPMorgan Chase & Co. grew its stake in Xencor by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock valued at $2,621,000 after acquiring an additional 3,635 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.